AB Science

NCT00789633

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

NCT00814073

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00812240

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

NCT01280565

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

NCT01449162

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

NCT01470131

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

NCT01433497

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

NCT01872598

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

NCT01694277

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

NCT02605044

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

NCT03766295

Masitinib Plus Gemcitabine in Pancreatic Cancer

NCT03761225

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT02009423

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

NCT03771040

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

NCT04333108

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

NCT03127267

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT05441488

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

NCT07174492

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

NCT05564169

Masitinib in Patients With Mild Alzheimer's Disease